St George’s, University of London research has found that a drug normally given to osteoporosis sufferers could provide effective pain relief to patients with knee and hip osteoarthritis.
Bisphosphonates are a group of drugs known to change the structure of bone and are most often prescribed to patients with osteoporosis, a condition characterised by fragile bones.
It is unknown, however, whether these drugs could be used to reduce pain and discomfort for patients with the joint condition osteoarthritis, which causes cartilage damage, bony growths and sore tissue.
The researchers used existing studies to assess the effectiveness of a variety of bisphosphonates in patients suffering from osteoarthritis of the hand, knee, spine and hips.
Of 3832 patients studied, in most cases these drugs showed limited pain relief. However, a few studies did show benefit; the bisphosphonate alendronate was found to be more effective for patients with hip osteoarthritis than existing pain relieving drugs. Moreover, the use of zoledronate and alendronate, specific forms of bisphosphonates, improved pain in patients with knee and hip osteoarthritis at six months —but longer term studies are needed.
Dr Nidhi Sofat, lead researcher, said: “Osteoarthritis is the most common form of arthritis worldwide. It causes damage to bone and cartilage in the joints of affected people. Most treatment is focused around pain relief, as no robust treatments have been discovered that slow down the progression of the disease.
“Our study looked at whether there were any bisphosphonate drugs that have been shown to influence pain and/or disease progression that could be used in osteoarthritis treatment.
“We found that, generally, bisphosphonates are ineffective at managing pain associated with osteoarthritis. But zoledronate and alendronate, which are specific forms of bisphosphonates, do show the potential for effective pain management specifically in patients with knee and hip osteoarthritis.
The Latest on: Bisphosphonates
- Equine Fatalities In Kentucky Were Up In 2018, And No One Is Quite Sure Why on February 20, 2019 at 3:29 pm
A new investigative development for 2018: Scollay said bone chips from deceased horses were sent to a laboratory for analysis, where she hopes scientists will discover whether the horses had been give... […]
- 7 Complications of Ankylosing Spondylitis and How to Avoid Them on February 20, 2019 at 12:00 pm
More than half of people with AS have this bone-weakening disease. Your doctor can help strengthen your bones and prevent fractures by prescribing bisphosphonates or other medications. Although your e... […]
- Osteoporosis Diagnosis, Care Suboptimal in Older Men on February 19, 2019 at 12:52 pm
However, in the overall cohort of men aged 70 years and older who met this threshold, only 12% had a dual-energy X-ray absorptiometry (DXA) scan to measure bone mineral density and only 5% received bi... […]
- Anti Osteoporosis Therapy and Fracture Healing Market Set for Rapid Growth During by 2024 on February 18, 2019 at 5:18 am
Feb 18, 2019 (Heraldkeeper via COMTEX) -- New York, February 18, 2019: Market Research Engine has published a new report titled as "Anti-Osteoporosis Therapy and Fracture Healing Market Size, By Drug ... […]
- Osteoporosis Often Missed in Elderly Men on February 15, 2019 at 9:00 am
Managing the disease included scans of bone mineral density, measuring levels of vitamin D, and treatment with vitamin D, calcium supplements and bisphosphonates (some brand names include Boniva, Acto... […]
- A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin on May 5, 2018 at 5:00 pm
1 Laboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA 92037, USA. 2 Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. 3 Department of ... […]
- Global Osteoporosis Treatment Market 2017-2025: Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, SERM and Rank Ligand Inhibitors on February 5, 2018 at 4:00 pm
The "Global Osteoporosis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been ad... […]
- Many more eligible for bisphosphonates after NICE lowers threshold to 1% on July 11, 2017 at 4:14 am
GPs should consider patients with lower risks of osteoporotic fracture for bisphosphonate treatment as the drugs are 'clinically effective' at this level, recommends a new NICE appraisal. New advice f... […]
- Review: Different bisphosphonates are equally effective and safe for preventing fragility fractures on March 20, 2017 at 2:14 pm
Included studies compared bisphosphonates with each other or control in women who were ≥ 65 years of age or ≤ 64 years of age with ≥ 1 risk factor, and men who were ≥ 75 years of age or ≤ 74 years of ... […]
via Google News and Bing News